BioWorld MedTech

Dec. 4, 2012

Supreme Court limits scope of review of Myriad to eligibility

The Supreme Court has opted to take the Myriad gene patent case, the outcome of which could fundamentally alter how life science companies draft patents for inventions involving genetic materials. Read More

Financings roundup: NanoString completes $15.3M Series E preferred issuance

NeuroMetrix wins FDA clearance for Sensus pain management system

Washington roundup: CMS eyes coverage review for dozens of products, procedures

Report from Europe: Cytomedix reports CE mark appoval for Angel cPRP system

Deals roundup: Volcano to acquire Crux for $36 million in cash

Agreements/contracts: Clinigence combines analytics with Spring Medical Systems

Med-Tech Notes

People in the News

Product Briefs

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...